Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01083368 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01083368 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 22 participants.
The verdict
NCT01083368, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may be a better way to block tumor growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with bevacizumab and to see how well it works in treating patients with hormone-resistant metastatic prostate cancer that did not respond to chemotherapy.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL bevacizumab
- GENETIC polymorphism analysis
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01083368
The ClinicalTrials.gov registry entry for NCT01083368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01083368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01083368 about?
NCT01083368 is a clinical study titled "Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy". RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill the...
What is the current status of trial NCT01083368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2009-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01083368?
The interventions under investigation include: laboratory biomarker analysis (OTHER), bevacizumab (BIOLOGICAL), polymorphism analysis (GENETIC), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01083368?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.